Ultragenyx药业 RARE 深 沪
已收盘 02-06 16:00:00 美东时间
24.70
+0.910
+3.83%
华盛通- 最 高24.87
- 今 开24.25
- 成交量 267.97万股
- 最 低 23.89
- 昨 收 23.79
- 总市值 23.83亿
- 52周最高 45.00
- 市盈率 静 --
- 换手率 2.78%
- 52周最低 18.41
- 委 比 -48.03%
- 总股本 9647.76万
- 历史最高 179.647
- 量 比 1.00
- 振 幅 4.12%
- 历史最低 18.41
- 每 手 1
- 风险率 5.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ultragenyx Pharmaceutical Inc. sieht sich einer Sammelklage wegen irreführender Angaben zu Studienergebnissen gegenüber
Ultragenyx Pharmaceutical Inc. sieht sich einer Sammelklage wegen irreführender Angaben zu Studienergebnissen gegenüber Gegen Ultragenyx Pharmaceutical Inc. wurde eine Sammelklage eingereicht. Das Unternehmen und mehrere leitende Angestellte werden beschuldigt, während des Zeitraums vom 3. August 20
02-05 08:44
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
9 Analysts Have This To Say About Ultragenyx Pharmaceutical
Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) were provided by 9 analysts...
02-04 06:00
Ultragenyx CFO Howard Horn Reports Disposal of Common Shares
Ultragenyx CFO Howard Horn Reports Disposal of Common Shares Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technolo
02-04 01:01
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq looked set for a firm open on Tuesday, stabilizing a
02-03 22:17
BUZZ-Ultragenyx rises as gene therapy shows long‑term benefit in rare childhood brain disorder
BUZZ-Ultragenyx rises as gene therapy shows long‑term benefit in rare childhood brain disorder ** Shares of drugmaker Ultragenyx RARE.O rise 4% to $25.75 in premarket trading ** Co says its experimental gene therapy helps children with Sanfilippo syndrome Type A - a rare disorder that rapidly damage
02-03 21:44
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $60 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintains $60 price target.
02-03 21:17
BRIEF-Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia)
BRIEF-Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia) Feb 3 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O : ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM DATA DEMONSTRATING TREATMENT WITH UX111 GENE THERAPY RESULTS
02-03 21:09
FDA prüft Zulassungsantrag für UX111 von Ultragenyx
FDA prüft Zulassungsantrag für UX111 von Ultragenyx Ultragenyx Pharmaceutical Inc. hat den Biologics License Application (BLA) für UX111, eine gentherapeutische Behandlung für Sanfilippo-Syndrom Typ A (MPS IIIA), im Januar 2026 erneut bei der US-amerikanischen Food and Drug Administration (FDA) eing
02-03 21:00
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review
Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On January 30, 2026...
01-30 22:22
